Compositions and methods for treating cancers

Abstract

The present invention relates to compositions and methods for treating of cancer. In some embodiments, the invention relates to the use of agents that can modulate a component in the CDX2-KLF4 signaling pathway to treat myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), adult T-cell leukaemia (ATLL), lymphoma, gastric cancer, multiple myeloma, or combinations thereof, or a condition associated with abnormal activity of the CDX2-KLF4 signaling pathway.

What is claimed: 
     
       1. A method of treating cancer in a human subject in need thereof, comprising administering to the subject in need of such treatment an effective amount of a compound of formula II, or a pharmacologically acceptable salt or solvate thereof: 
       
         
           
           
               
               
           
         
         wherein the human subject has an abnormal level of Myc activity and the Myc activity in the human subject is decreased after the treatment, 
         and wherein the cancer is acute myeloid leukemia, or myelodysplastic syndrome (MDS). 
       
     
     
       2. The method of  claim 1 , wherein the cancer is myelodysplastic syndrome (MDS). 
     
     
       3. The method of  claim 1 , wherein the cancer is acute myeloid leukemia. 
     
     
       4. A method of treating a myelodysplastic syndrome (MDS) in a human subject, comprising administering to a human subject identified as suffering from a MDS an effective amount of a compound capable of decreasing the Myc activity in the human subject, or a pharmacologically acceptable salt or solvate thereof, wherein the compound has formula II: 
       
         
           
           
               
               
           
         
       
     
     
       5. The method of  claim 4 , wherein the compound is administered to a human patient identified as having abnormally high level of Myc activity. 
     
     
       6. The method of  claim 4 , wherein said compound is administered as part of a combination therapy. 
     
     
       7. The method of  claim 6 , wherein the combination therapy comprises radiotherapy. 
     
     
       8. The method of  claim 6 , wherein the combination therapy comprises chemotherapy. 
     
     
       9. The method of  claim 4 , wherein said compound is administered with a dosage of about 125 mg/m 2 . 
     
     
       10. The method of  claim 4 , wherein said compound is administered two times per week for four weeks.